- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Journal: Biological activities of siRNA-loaded lanthanum phosphate nanoparticles on colorectal cancer. (Pubmed Central) - Jun 22, 2021
Lanthanum can reduce absorption of phosphate by forming lanthanum phosphate complexes after oral administration of lanthanum carbonate tablets (FOSRENOL®) in patients...Furthermore, significant tumor growth inhibition was observed in both transgenic C57BL/6-Apc/Nju cancer mouse model and AOM/DSS chemically induced orthotopic colorectal cancer mouse model after intestinal instillation administration of CS/LaP/siEGFR NPs. Therefore, the lanthanum-based siRNA delivery system would provide a potential and efficient strategy for the treatment of colorectal cancers.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Phase classification: Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD (clinicaltrials.gov) - Jun 9, 2021
P2a, N=35, Completed,
Therefore, the lanthanum-based siRNA delivery system would provide a potential and efficient strategy for the treatment of colorectal cancers. Phase classification: P2 --> P2a
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Retrospective data, Journal: Meta-Analysis Treatment Hyperphosphatemia Chronic Renal Failure Based on Nano Lanthanum Hydroxide. (Pubmed Central) - Jun 1, 2021
WMD=0.41, 95% CI: -0.48~0.34; the difference between the lanthanum carbonate and calcium carbonate in the control of the blood phosphorus level was statistically significant; WMD = 0.19, 95% CI: -0.25~0.13, lanthanum carbonate and calcium carbonate were statistically significant in blood control calcium level; WMD = 174.66, 95% CI: -150.86~150.46, lanthanum carbonate and calcium carbonate were statistically significant in the control of blood PIH level; the difference was statistically significant. Lanthanum carbonate can significantly reduce blood phosphorus and PIH complicated hyperphosphatemia, and has no significant effect on blood calcium, which is superior to calcium carbonate in effectiveness.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Journal: Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the IMpact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial. (Pubmed Central) - May 25, 2021
The IMpact of Phosphate Reduction On Vascular End-points in CKD (IMPROVE-CKD) study is an international, multi-centre, randomized, placebo-controlled trial investigating the effect of the phosphate binder lanthanum carbonate on intermediate cardiovascular markers in patients with stage 3b-4 CKD...AAC was associated with older age, male sex, diabetes, CVD, higher diastolic BP, dyslipidaemia (and use of statins), smoking, larger waist circumference and increased PWV. In conclusion, IMPROVE-CKD participants had high baseline risk for cardiovascular events, as suggested by high baseline PWV and AAC values.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Clinical, Journal: Investigation of the clinical significance and pathological features of lanthanum deposition in the gastric mucosa. (Pubmed Central) - May 11, 2021
The specific endoscopic features of La deposition are associated with the infiltration of histiocytes, which represents the body's normal response to foreign bodies. Trial registry The protocol was registered in the University Hospital Medical Information Network Clinical Trial Registry (UMIN000038929, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000044393 ).
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Journal: The Pharmacological Effect and Mechanism of Lanthanum Hydroxide on Vascular Calcification Caused by Chronic Renal Failure Hyperphosphatemia. (Pubmed Central) - May 1, 2021
Rats were randomly allocated to five groups: normal diet control, CKD hyperphosphatemia model, CKD model treated with lanthanum hydroxide, CKD model receiving lanthanum carbonate treatment, together with CKD model receiving calcium carbonate treatment...Lanthanum hydroxide evidently downregulated NF-κB, BMP-2, Runx2, and TRAF6 expression. Lanthanum hydroxide protects against renal failure and reduces the phosphorus level in serum to postpone vascular calcification progression.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Journal: Strong adsorption of phosphate by amorphous lanthanum carbonate nano-adsorbents. (Pubmed Central) - Apr 13, 2021
For a real effluent, the P concentration was efficiently reduced from 3.2 mg P/L to below 0.5 mg P/L at a dose of 0.5 g/L LC. All the results suggested that LC can serve as a promising adsorbent for P removal in a wide range of pH, and thus could meet the stricter discharge regulations from actual wastewater.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Journal: Unexpected deposits in the upper gastrointestinal tract : When medical history matters (Pubmed Central) - Mar 11, 2021
In order to regulate their phosphate uptake, patients with end-stage renal disease rely on phosphate binders such as lanthanum carbonate (LC)...Evaluation of the patient's medical and especially drug history is essential to obtain the appropriate diagnosis. We present an overview of the clinical presentation and histological differential diagnosis of LC.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Clinical, Journal: A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). (Pubmed Central) - Mar 10, 2021
In patients with stage 3b/4 CKD, treatment with lanthanum over 96 weeks did not affect arterial stiffness or aortic calcification compared with placebo. These findings do not support the role of intestinal phosphate binders to reduce cardiovascular risk in patients with CKD who have normophosphatemia.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Journal: Intratumoral inorganic phosphate deprivation: A new anticancer strategy? (Pubmed Central) - Jan 26, 2021
On the other hand, phosphate binder (e.g. La (CO), Fosrenols) has been clinically approved to treat hyperphosphatemia, a metabolic disease characterized by a high serum phosphate level...Secondly, a rabbit VX2 liver tumor was set up for the local-regional therapy model, where lanthanum acetate was intratumorally administered by the standard transcatheter arterial chemoembolization procedure, and it significantly reduced intratumoral Pi concentration. Therefore, Pi deprivation by phosphate binder might be a new anticancer strategy if reducing phosphate burden could effectively arrest tumor growth and delay metastatic progression.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Review, Journal: Review of the diagnosis of gastrointestinal lanthanum deposition. (Pubmed Central) - Jan 23, 2021
Lanthanum carbonate is used for treatment of hyperphosphatemia mostly in patients with chronic renal failure...In the gastric mucosa with atrophy, lanthanum-related lesions likely appear as annular or granular whitish lesions. Moreover, these white lesions are probably more frequently observed in the lower part of the stomach, where intestinal metaplasia begins.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Journal: Suppression of phosphorus release from sediment using lanthanum carbonate as amendment. (Pubmed Central) - Jan 9, 2021
The addition of LC into sediment could greatly improve the HPO uptake ability for the sediment, and the enhancement of HPO adsorption onto the sediment by the added LC increased as the increase of the amendment dosage and the initial HPO concentration. All results suggest that LC could serve as a promising amendment material for the control of sedimentary P release.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Trial completion date, Trial primary completion date: LaCa: Lanthanum Carbonate (Fosrenol (clinicaltrials.gov) - Jan 8, 2021
P3, N=35, Recruiting,
All results suggest that LC could serve as a promising amendment material for the control of sedimentary P release. Trial completion date: May 2020 --> Dec 2022 | Trial primary completion date: May 2020 --> Dec 2022
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Trial completion date, Trial initiation date, Trial primary completion date: Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders (clinicaltrials.gov) - Dec 10, 2020
P4, N=44, Not yet recruiting,
Finally, the mechanism study by XPS, XRD, and IR demonstrated that the ligand exchange played an important role in the electro-assisted phosphate uptake process. Trial completion date: Dec 2020 --> Sep 2022 | Initiation date: Dec 2020 --> Sep 2021 | Trial primary completion date: Dec 2020 --> Sep 2022
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Journal: The Formation of Perovskite during the Combustion of an Energy-Rich Glycine-Nitrate Precursor. (Pubmed Central) - Nov 18, 2020
SHS was found to be the most productive regime for the formation of perovskite because of its ability to develop high temperatures in the reaction zone, which led to a reduced content of the thermally stable lanthanum carbonate impurities and to an increased yield and crystallite size of the perovskite phase. The reasons for the better crystallinity and purity of LaCrO as compared with LaMnO is also discussed, namely the low temperatures of the onset of the thermolysis, the fast rate of combustion, and the favorable thermodynamics for the achievement of high temperatures in the reaction zone.
- |||||||||| Velphoro (sucroferric oxyhydroxide) / Fresenius Kabi, Vifor, Kissei
Preclinical, Journal: A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study. (Pubmed Central) - Nov 7, 2020
The reasons for the better crystallinity and purity of LaCrO as compared with LaMnO is also discussed, namely the low temperatures of the onset of the thermolysis, the fast rate of combustion, and the favorable thermodynamics for the achievement of high temperatures in the reaction zone. These results suggest that coadministration of PA21 and calcium carbonate showed good and relatively stable efficacy throughout the range of the gastrointestinal pH and that combining lanthanum carbonate hydrate and ferric citrate hydrate with calcium carbonate may not produce the expected efficacy under certain conditions.
- |||||||||| lanthanum polystyrene sulfonate powder / Liaoning Grand Nuokang Biopharma
Enrollment open, Trial initiation date: To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder (clinicaltrials.gov) - Oct 28, 2020
P1/2, N=48, Recruiting,
These results suggest that coadministration of PA21 and calcium carbonate showed good and relatively stable efficacy throughout the range of the gastrointestinal pH and that combining lanthanum carbonate hydrate and ferric citrate hydrate with calcium carbonate may not produce the expected efficacy under certain conditions. Not yet recruiting --> Recruiting | Initiation date: Jul 2020 --> Oct 2020
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
[VIRTUAL] Treatment of Uremic Tumoral Calcinosis in Maintenance Hemodialysis Patients () - Oct 27, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_3843;
Based on the levels of iPTH, cases were categorized into two different groups: PTX treatment group was associated with high levels of iPTH, while drug treatment group (lanthanum carbonate or sevelamer with STS) was lower iPTH...Funding Government Support - Non-U. S.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
[VIRTUAL] Hospital Admission Rates Among Hemodialysis Patients with Persistent Hyperphosphatemia Who Were Prescribed Changes in Phosphate Binder Treatment: A Retrospective Analysis of Real-World Data (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_939;
We identified 1,076 patients with baseline hyperphosphatemia despite SC prescription who switched PB therapy, including 319 patients with SO therapy and 757 patients with Non-SO therapy. Patients switched to SO had 27 fewer hospital admissions per 100 patient-years compared to patients with Non-SO therapy (Table 1) Conclusion In a retrospective database analysis of hemodialysis patients previously treated with sevelamer carbonate and switched to SO or Non-SO phosphate binder therapy, patients switched to SO monotherapy had a lower rate of hospital admissions than patients switched to other, non-SO phosphate bindersVariables included in the Poisson regression model: HD vintage, congestive heart failure status, serum phosphorus and categories, iPTH and categories, (iPTH)2 Funding: Commercial Support
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Clinical, Review, Journal: Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease. (Pubmed Central) - Sep 30, 2020
Moreover, the use of lanthanum carbonate has been associated with better nutritional status compared to other phosphate binders, lower risk for hypercalcemia than calcium-containing binders, and amelioration of mild metabolic acidosis contrary to sevelamer hydrochloride. Main adverse effects include nausea, alkaline gastric reflux, gastric deposition of lanthanum, gastrointestinal obstruction, subileus, ileus, perforation, fecal impaction, and reduction of gastrointestinal absorption of some drugs including statins, angiotensin-converting enzyme inhibitors and some antibiotics such as fluoroquinolones or tetracyclines.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Trial initiation date: Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders (clinicaltrials.gov) - Sep 17, 2020
P4, N=44, Not yet recruiting,
Main adverse effects include nausea, alkaline gastric reflux, gastric deposition of lanthanum, gastrointestinal obstruction, subileus, ileus, perforation, fecal impaction, and reduction of gastrointestinal absorption of some drugs including statins, angiotensin-converting enzyme inhibitors and some antibiotics such as fluoroquinolones or tetracyclines. Initiation date: Sep 2020 --> Dec 2020
|
